From multi-omics to cancer digital twins: Novel paradigm in cancer research and treatment response

References

[1] WuX, YangX, DaiY, et al. Single-cell sequencing to multi-omics: technologies and applications. Biomark Res. 2024;12(1):110.

[2] de VisserKE, JoyceJA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374-403.

[3] ChenC, WangJ, PanD, et al. Applications of multi-omics analysis in human diseases. MedComm. 2023;4(4):e315.

[4] MansoorS, HamidS, TuanTT, Park J-E, ChungYS. Advance computational tools for multiomics data learning. Biotechnol Adv. 2024;77:108447.

[5] IsavandP, Aghamiri SS, AminR. Applications of multimodal artificial intelligence in non-Hodgkin lymphoma B cells. Biomedicines. 2024;12(8):1753.

[6] ZhangW, YeB, SongY, et al. Integrating multi-omics features enables non-invasive early diagnosis and treatment response prediction of diffuse large B-cell lymphoma. Clin Transl Med. 2025;15(1):e70174.

[7] HalabiS, LiC, LuoS. Developing and validating risk assessment models of clinical outcomes in modern oncology. JCO Precis Oncol. 2019;3:1-12.

[8] KatsoulakisE, WangQ, WuH, et al. Digital twins for health: a scoping review. npj Digital Med. 2024;7(1):77.

[9] MollicaL, LeliC, SottotettiF, Quaglini S, LocatiLD, MarcegliaS. Digital twins: a new paradigm in oncology in the era of big data. ESMO Real World Data Digit Oncol. 2024;5:100056.

[10] StahlbergEA, Abdel-Rahman M, AguilarB, et al. Exploring approaches for predictive cancer patient digital twins: opportunities for collaboration and innovation. Front Digit Health. 2022;4:1007784.

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Discovery published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.